Ken Griffin Nkarta, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$5.27 - $10.82 $20,553 - $42,198	-3,900 Reduced 8.32%	43,000 $254,000
Q1 2024 May 15, 2024	BUY	$5.59 - $15.71 $133,601 - $375,469	23,900 Added 103.91%	46,900 $506,000
Q4 2023 Feb 14, 2024	BUY	$1.31 - $6.6 $24,235 - $122,100	18,500 Added 411.11%	23,000 $151,000
Q3 2023 Nov 14, 2023	BUY	$1.39 - $2.29 $1,112 - $1,832	800 Added 21.62%	4,500 $6,000
Q2 2023 Aug 14, 2023	SELL	$2.19 - $5.17 $13,578 - $32,054	-6,200 Reduced 62.63%	3,700 $8,000
Q1 2023 May 15, 2023	SELL	$3.37 - $6.3 $1,685 - $3,150	-500 Reduced 4.81%	9,900 $35,000
Q4 2022 Feb 14, 2023	SELL	$5.14 - $14.35 $928,284 - $2.59 Million	-180,600 Reduced 94.55%	10,400 $62,000
Q3 2022 Nov 14, 2022	SELL	$12.27 - $18.39 $596,322 - $893,754	-48,600 Reduced 20.28%	191,000 $2.51 Million

124

66.2M

142K

43.1K

Ticker NKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,656,800
Market Cap $157M
Description
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.